Risk of pancreatitis and pancreatic carcinoma for anti-diabetic medications: findings from real-world safety data analysis and systematic review and meta-analysis of randomized controlled trials
CONCLUSION: Evidence from the post-marketing safety data analysis identified a strong association between incretin mimetics and pancreatic events. Fewer events in RCTs may justify insignificant meta-analysis results.PMID:37986140 | DOI:10.1080/14740338.2023.2284992 (Source: Expert Opinion on Drug Safety)
Source: Expert Opinion on Drug Safety - November 21, 2023 Category: Drugs & Pharmacology Authors: Asif Muhammad Christy Thomas Vivekanandan Kalaiselvan Krishna Undela Source Type: research
Paradigm shift in the management of metabolic diseases - next generation incretin therapy
Endocrinology. 2023 Nov 10:bqad166. doi: 10.1210/endocr/bqad166. Online ahead of print.ABSTRACTRecently impressive weight loss has been reported for novel incretin therapies based on dual and triple hormone receptor coagonists. These agents have potential as being positioned as early therapeutics for metabolic diseases where weight loss is preferred, such as type 2 diabetes, obesity, cardiovascular diseases and non-alcoholic liver disease. This development will change the landscape of future therapy and also place weight reduction at the centerpiece for therapy of metabolic diseases.PMID:37951841 | DOI:10.1210/endocr/bqad1...
Source: Endocrinology - November 11, 2023 Category: Endocrinology Authors: Bo Ahr én Source Type: research
Paradigm Shift in the Management of Metabolic Diseases-Next-Generation Incretin Therapy
Endocrinology. 2023 Nov 2;164(12):bqad166. doi: 10.1210/endocr/bqad166.ABSTRACTRecently impressive weight loss has been reported for novel incretin therapies based on dual-and triple-hormone receptor coagonists. These agents have potential as being positioned as early therapeutics for metabolic diseases for which weight loss is preferred, such as type 2 diabetes, obesity, cardiovascular diseases, and nonalcoholic liver disease. This development will change the landscape of future therapy and also place weight reduction at the centerpiece for therapy of metabolic diseases.PMID:37951841 | DOI:10.1210/endocr/bqad166 (Source: Endocrinology)
Source: Endocrinology - November 11, 2023 Category: Endocrinology Authors: Bo Ahr én Source Type: research
Paradigm Shift in the Management of Metabolic Diseases-Next-Generation Incretin Therapy
Endocrinology. 2023 Nov 2;164(12):bqad166. doi: 10.1210/endocr/bqad166.ABSTRACTRecently impressive weight loss has been reported for novel incretin therapies based on dual-and triple-hormone receptor coagonists. These agents have potential as being positioned as early therapeutics for metabolic diseases for which weight loss is preferred, such as type 2 diabetes, obesity, cardiovascular diseases, and nonalcoholic liver disease. This development will change the landscape of future therapy and also place weight reduction at the centerpiece for therapy of metabolic diseases.PMID:37951841 | DOI:10.1210/endocr/bqad166 (Source: Endocrinology)
Source: Endocrinology - November 11, 2023 Category: Endocrinology Authors: Bo Ahr én Source Type: research
Paired box 6 gene delivery preserves beta cells and improves islet transplantation efficacy
In this study, we identified paired box 6 (PAX6) as a critical regulator of beta cell survival. Under diabetic conditions, the human beta cell line EndoC-βH1, db/db mouse and human islets displayed dampened insulin and incretin signalings and reduced beta cell survival, which were alleviated by PAX6 overexpression. Adeno-associated virus (AAV)-mediated PAX6 overexpression in beta cells of streptozotocin-induced diabetic mice and db/db mice led to a sustained maintenance of glucose homeostasis. AAV-PAX6 transduction in human islets reduced islet graft loss and improved glycemic control after transplantation into immunodefi...
Source: Molecular Medicine - November 7, 2023 Category: Molecular Biology Authors: Wing Yan So Yilie Liao Wai Nam Liu Guy A Rutter Weiping Han Source Type: research
Optimizing expression, purification, structural and functional assessments of a novel dimeric incretin (GLP-1cpGLP-1)
In this study, a new dimeric GLP-1 analogue (GLP-1cpGLP-1) was designed by inserting human insulin C-peptide (CP) in the middle of a dimer of [Gly8] GLP-1 (7-36). Then, the dimeric incretin (GLP-1cpGLP-1) was ligated to human αB-crystallin (αB-Cry) to create a hybrid protein, abbreviated as αB-GLP-1cpGLP-1. The constructed gene was well expressed in the bacterial host system. After specific chemical release from the hybrid protein, the dimeric incretin was purified by size exclusion chromatography (SEC). Finally, the RP-HPLC analysis indicated a purity of >99 % for the dimeric incretin. The secondary structure assess...
Source: Biochimie - November 6, 2023 Category: Biochemistry Authors: Rawayh Albaghlany Mohammad Bagher Shahsavani Masaru Hoshino Ali Akbar Moosavi-Movahedi Younes Ghasemi Reza Yousefi Source Type: research
Optimizing expression, purification, structural and functional assessments of a novel dimeric incretin (GLP-1cpGLP-1)
In this study, a new dimeric GLP-1 analogue (GLP-1cpGLP-1) was designed by inserting human insulin C-peptide (CP) in the middle of a dimer of [Gly8] GLP-1 (7-36). Then, the dimeric incretin (GLP-1cpGLP-1) was ligated to human αB-crystallin (αB-Cry) to create a hybrid protein, abbreviated as αB-GLP-1cpGLP-1. The constructed gene was well expressed in the bacterial host system. After specific chemical release from the hybrid protein, the dimeric incretin was purified by size exclusion chromatography (SEC). Finally, the RP-HPLC analysis indicated a purity of >99 % for the dimeric incretin. The secondary structure assess...
Source: Biochimie - November 6, 2023 Category: Biochemistry Authors: Rawayh Albaghlany Mohammad Bagher Shahsavani Masaru Hoshino Ali Akbar Moosavi-Movahedi Younes Ghasemi Reza Yousefi Source Type: research
Optimizing expression, purification, structural and functional assessments of a novel dimeric incretin (GLP-1cpGLP-1)
In this study, a new dimeric GLP-1 analogue (GLP-1cpGLP-1) was designed by inserting human insulin C-peptide (CP) in the middle of a dimer of [Gly8] GLP-1 (7-36). Then, the dimeric incretin (GLP-1cpGLP-1) was ligated to human αB-crystallin (αB-Cry) to create a hybrid protein, abbreviated as αB-GLP-1cpGLP-1. The constructed gene was well expressed in the bacterial host system. After specific chemical release from the hybrid protein, the dimeric incretin was purified by size exclusion chromatography (SEC). Finally, the RP-HPLC analysis indicated a purity of >99 % for the dimeric incretin. The secondary structure assess...
Source: Biochimie - November 6, 2023 Category: Biochemistry Authors: Rawayh Albaghlany Mohammad Bagher Shahsavani Masaru Hoshino Ali Akbar Moosavi-Movahedi Younes Ghasemi Reza Yousefi Source Type: research
Optimizing expression, purification, structural and functional assessments of a novel dimeric incretin (GLP-1cpGLP-1)
In this study, a new dimeric GLP-1 analogue (GLP-1cpGLP-1) was designed by inserting human insulin C-peptide (CP) in the middle of a dimer of [Gly8] GLP-1 (7-36). Then, the dimeric incretin (GLP-1cpGLP-1) was ligated to human αB-crystallin (αB-Cry) to create a hybrid protein, abbreviated as αB-GLP-1cpGLP-1. The constructed gene was well expressed in the bacterial host system. After specific chemical release from the hybrid protein, the dimeric incretin was purified by size exclusion chromatography (SEC). Finally, the RP-HPLC analysis indicated a purity of >99 % for the dimeric incretin. The secondary structure assess...
Source: Biochimie - November 6, 2023 Category: Biochemistry Authors: Rawayh Albaghlany Mohammad Bagher Shahsavani Masaru Hoshino Ali Akbar Moosavi-Movahedi Younes Ghasemi Reza Yousefi Source Type: research
Secondary diabetes mellitus in pheochromocytomas and paragangliomas
AbstractSecondary diabetes mellitus (DM) in secretory pheochromocytomas and paragangliomas (PPGLs) is encountered in up to 50% of cases, with its presentation ranging from mild, insulin resistant forms to profound insulin deficiency states, such as diabetic ketoacidosis and hyperglycemic hyperosmolar state. PPGLs represent hypermetabolic states, in which adrenaline and noradrenaline induce insulin resistance in target tissues characterized by aerobic glycolysis, excessive lipolysis, altered adipokine expression, subclinical inflammation, as well as enhanced gluconeogenesis and glucogenolysis. These effects are mediated bot...
Source: Endocrine - November 5, 2023 Category: Endocrinology Source Type: research
Pharmacological modulation of adaptive thermogenesis: new clues for obesity management?
AbstractBackgroundAdaptive
thermogenesis represents the main mechanism through which the body generates heat in response to external stimuli, a phenomenon that includes shivering and non-shivering thermogenesis. The non-shivering thermogenesis is mainly exploited by adipose tissue characterized by a brown aspect, which specializes in energy dissipation. A decreased amount of brown adipose tissue has been observed in ageing and chronic illnesses such as obesity, a worldwide health problem characterized by dysfunctional adipose tissue expansion and associated cardiometabolic complications. In the last decades, the discov...
Source: Journal of Endocrinological Investigation - November 1, 2023 Category: Endocrinology Source Type: research
Secondary diabetes mellitus in pheochromocytomas and paragangliomas
AbstractSecondary diabetes mellitus (DM) in secretory pheochromocytomas and paragangliomas (PPGLs) is encountered in up to 50% of cases, with its presentation ranging from mild, insulin resistant forms to profound insulin deficiency states, such as diabetic ketoacidosis and hyperglycemic hyperosmolar state. PPGLs represent hypermetabolic states, in which adrenaline and noradrenaline induce insulin resistance in target tissues characterized by aerobic glycolysis, excessive lipolysis, altered adipokine expression, subclinical inflammation, as well as enhanced gluconeogenesis and glucogenolysis. These effects are mediated bot...
Source: Endocrine - October 31, 2023 Category: Endocrinology Source Type: research
Retatrutide: a triple incretin receptor agonist for obesity management
Expert Opin Investig Drugs. 2023 Oct 30. doi: 10.1080/13543784.2023.2276754. Online ahead of print.ABSTRACTINTRODUCTION: Obesity treatment is evolving rapidly with the emergence of agents targeting incretin receptors. Retatrutide, a triple agonist of these receptors, shows promise in obesity management.AREAS COVERED: Retatrutide, in phase-2 trials, exhibited significant reductions in glycated hemoglobin (HbA1c) and dose-dependent weight loss in individuals with type 2 diabetes mellitus (T2DM). In non-T2DM individuals, it produced substantial weight loss and improved glucose levels, albeit with gastrointestinal side effects...
Source: Expert Opinion on Investigational Drugs - October 30, 2023 Category: Drugs & Pharmacology Authors: Avik Ray Source Type: research
